StoneX Group’s X4 Pharmaceuticals XFOR Stock Holding History

StoneX Group’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-392	Closed	-$9.85K	–	456
2023 Q4	$9.85K	Buy	+392	New	+$9.53K	0.01%	320

Other funds holding XFOR

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

StoneX Group's XFOR Position: Q1 2024 in Review

StoneX Group sold out of X4 Pharmaceuticals (XFOR) in Q1 2024, closing a stake of 392 shares — an estimated $9.85K sold.

StoneX Group first reported a position in XFOR in Q4 2023 and held it in 1 quarter. The position peaked at $9.85K in Q4 2023. 96 funds tracked by Wall St. Rank hold XFOR as of Q1 2024.

StoneX Group reported no remaining X4 Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
StoneX Group sold 392 X4 Pharmaceuticals shares in Q1 2024, an estimated $9.85K.
StoneX Group first reported a position in X4 Pharmaceuticals in Q4 2023 and held it in 1 quarter.
StoneX Group's X4 Pharmaceuticals position peaked at $9.85K in Q4 2023.
96 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2024.

Based on StoneX Group's 13F filing for Q1 2024, filed 1 May 2024.